Japan To Be Site Of New Trials For Novartis H1N1 Vaccine
This article was originally published in PharmAsia News
Executive Summary
Japan has been chosen by Swiss drug maker Novartis as the third country in which it plans to conduct clinical trials for its H1N1 flu vaccine. Japan has only four companies that can produce vaccine, so the government is considering companies abroad for additional supplies. Novartis, which already has its vaccine in trials in Switzerland and Germany, plans to begin trials in Japan in mid-September, with the Japanese trials to be overseen by the local subsidiary, Novartis Pharma KK. (Click here for more - a subscription may be required
You may also be interested in...
Mustang Bio Enters Race For CAR-T In Autoimmune Disease
The biotech company’s CEO talked to Scrip about plans to bring the CD20-targeting CAR-T MB-106 into an investigator-sponsored Phase I trial later this year.
Aldeyra Hopes To Refile Dry Eye Drug Reproxalap Later In 2024
Following an FDA complete response letter last November, Aldeyra has agreed with the agency on a trial design to demonstrate efficacy in ocular discomfort, which the company can complete this year.
Colorado Price Cap Plan For Enbrel Draws Amgen Lawsuit; Cosentyx, Stelara ‘Affordability’ Reviews Pending
However, the state's recently formed prescription drug affordability board found Gilead’s Genvoya and Vertex’s Trikafta to be affordable.